A drug with or without radiation for HER2-positive breast cancer that spread to the brain
Original title: Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage trial comparing two treatment plans in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a cancer drug with and without radiation.
Who this trial is for. This trial is for people with HER2-positive advanced breast cancer that spread to the brain. It compares the drug Trastuzumab Rezetecan plus radiation to the drug alone.
Where it stands. The trial has not reported results. It plans to include 224 people, split evenly between the two groups. People stay on treatment until the cancer grows or side effects get too hard. The answer is not in yet.
What this means, and what it doesn't
What it could mean: If this fits your situation, you could ask your care team about this trial. They can help you weigh it against your other options.
What it doesn't mean: This does not mean adding radiation works better. A trial is a test, not a proven treatment. Being in one is not a promise of benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.